Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Venture Financing 12
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Partnerships 16
Aeglea BioTherapeutics Enters into Agreement with Merck 16
Licensing Agreements 17
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
Equity Offering 18
Aeglea BioTherapeutics Prices Public Offering of Shares for USD36 Million 18
Aeglea BioTherapeutics Raises USD12.3 Million in Public Offering of Shares 20
Aeglea BioTherapeutics Raises USD54.8 million in IPO 21
Aeglea BioTherapeutics Inc – Key Competitors 22
Aeglea BioTherapeutics Inc – Key Employees 23
Aeglea BioTherapeutics Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 09, 2018: Aeglea Biotherapeutics provides corporate update and reports second quarter 2018 financial results 25
May 08, 2018: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results 27
Mar 13, 2018: Aeglea BioTherapeutics Reports Q4 and Full Year 2017 Financial Results 29
Nov 07, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results 30
Aug 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results 31
May 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results 32
Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 33
Corporate Communications 35
Jul 16, 2018: Aeglea BioTherapeutics names Dr. Bryan Lawlis as board director 35
Jul 20, 2017: Aeglea BioTherapeutics Announces Leadership Change 36
Jul 10, 2017: Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer 37
Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 38
Product News 39
11/29/2017: Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102) 39
09/06/2017: Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency 40
05/23/2017: Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update 41
04/03/2018: Aeglea BioTherapeutics to Present New Phase 1/2 Trial Results in Arginase 1 Deficiency at the 2018 ACMG Annual Clinical Genetics Meeting 43
03/26/2018: Aeglea BioTherapeutics Appoints Dr. Ivana Magovcevic-Liebisch to Board of Directors 44
03/13/2018: Aeglea BioTherapeutics Provides Key Clinical Data Update from Phase 1/2 Trial in Arginase 1 Deficiency 45
03/06/2018: Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders 47
02/28/2017: Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at Keystone Symposia Conference on Tumor Metabolism 48
Clinical Trials 49
Apr 05, 2018: Aeglea BioTherapeutics to Present Pegzilarginase Phase 1 Dose Escalation Data in Patients with Advanced Solid Tumors at 2018 AACR Annual Meeting 49
Apr 02, 2018: Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA (Pembrolizumab) Combination Trials 50
Mar 08, 2018: Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase 51
Jan 18, 2018: Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference 52
Nov 02, 2017: Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting 53
Mar 29, 2017: Aeglea BioTherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting 54
Mar 23, 2017: Aeglea BioTherapeutics to Present Topline Data from Phase 1 Trial of AEB1102 for Treatment of Arginase I Deficiency at 2017 ACMG Annual Clinical Genetics Meeting 55
Jan 17, 2017: Aeglea BioTherapeutics to Present New Data at 2017 ACMG Annual Clinical Genetics Meeting 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Aeglea BioTherapeutics Enters into Agreement with Merck 16
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
Aeglea BioTherapeutics Prices Public Offering of Shares for USD36 Million 18
Aeglea BioTherapeutics Raises USD12.3 Million in Public Offering of Shares 20
Aeglea BioTherapeutics Raises USD54.8 million in IPO 21
Aeglea BioTherapeutics Inc, Key Competitors 22
Aeglea BioTherapeutics Inc, Key Employees 23
Aeglea BioTherapeutics Inc, Subsidiaries 24
List of Figures
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9